Screening that will eliminate issues:
Non-invasive paternity testing for High Risk Mothers
NIPT (non-invasive paternity testing) will soon be a reality in Sri
Lanka, with the Credence Genomics partnering with YourGene from Taiwan
to set up the test. Globally NIPT has been offered as a screening test
for high risk pregnant women after the 10th week of pregnancy.
Conventionally women who have late pregnancies are at risk of having
children with congenital defects especially chromosomal abnormalities.
Apart from these families, with raised risk inherited disorders can also
use the test as a screening test.
Safe
At present most of the women in this category have to undergo an
amniocentesis or a chorionic villous sampling, both of which are
invasive and carry a risk of miscarriage. Hence not only is the test
safer, it can also be done much earlier in the pregnancy. Dr. Padmapani
Padeniya said, "Credence Genomics has created history with the
introduction of Non Invasive Prenatal Testing for Sri Lankan pregnant
population. This is another first in Sri Lanka by Credence Genomics.

Dr. Padmapani Padeniya of Credence Genomics and Keng Hsu -
MD of Yourgene Taiwan exchange documents |
Pregnant women can now screen their pregnancies for commonly
available aneuploidies including Down Syndrome, Patau Syndrome and
Edward Syndrome. Since this test is 99% sensitive and does not carry the
potential risk of miscarriage, this would be a popular test for all
expectant mothers".
Yourgene based in Taiwan has established its track record in the area
of Non-invasive paternity testing over the past few years and garnered
strong positioning of its representative platform in the South East
Asian market.
As one of the largest NIPT test provider in the region, Yourgene
identified Credence Genomics in Sri Lanka as the perfect partner to
offer NIPT and work on further collaborative developments.
Keng Hsu - MD of Yourgene Taiwan said "It was wonderful to have the
opportunity to work with such well reputed partners in Sri Lanka who are
well known outside Sri Lanka for their infectious disease detection
services.
We look forward to providing our services to the highest standard, to
Credence Genomic's client in the region".
Credence Genomics is Sri Lanka's only DNA Diagnostics facility using
the latest techniques of NGS (Next Generation Sequencing) to diagnose
infection, predict cancer and treat cancer with precision medicine.
With over 98 percent accuracy Credence delivers competitively priced
DNA diagnostics to assist physicians and consultant specialists use the
cutting edge field of genomics.
Credence Genomics also offers genetic counseling and has an expert
panel of consultants working in conjunction with its team.
Credence's cutting edge diagnostic products deliver accurate results
in half the time in the areas of infection, cancer and precision
medicine.
Dr. Vaz Gnanam CEO/Director said "We are thrilled to be working with
the Yourgene team on offering the NIPT test to the Sri Lankan market.
Not only would this have a positive impact in terms of a screening
test with less risk but it would also have a positive impact for couples
who would like an accurate alternative to what is on offer now." |